PREDICTOR SERUM BIOMARKERS OF CARDIOVASCULAR DAMAGE IN COVID-19

Purpose of the study: Retrospective assessment of the peculiarities of changes in the clinical and laboratory parameters of patients with COVID-19 and concomitant cardiovascular pathology. Materials and methods.A retrospective analysis of medical records of 92 patients was.All patients with COVID-19 underwent routine blood tests, including a complete blood count, coagulation profile, lipid spectrum and liver and kidney function, inflammatory biomarkers.Results.According to the results of the study, in the included 92 patients with COVID-19, CVD was found in 32 patients (35.7%).When studying the medical records of patients of the first group with COVID-19 without cardiovascular pathology, the following data of clinical and laboratory parameters were obtained: in the study of a detailed biochemical blood test, an excess of the reference (10-120 μg / l) values of ferritin (192.4 μg / l, p <0.05), C-reactive protein (18.19 mg / l versus the reference 0-5 mg / l, p <0.05), hemostasiogram values: increased fibrinogen (7.25 g / l versus 2.76-4.71g / l, p <0 , 05), Ddimers (437.8 ng / ml versus 0-255 ng / ml, p <0.05).In the second group COVID-19 with cardiovascular pathology (n = 30), the following data of clinical and laboratory parameters were obtained: when studying a detailed biochemical analysis, an excess of ferritin content was revealed (518.36 μg / l versus 192.4 μg / l, the difference is 169.42%,p < 0.05), C-reactive protein (38.67 mg / L versus 18.19 mg / L, the difference is 112.6%, p <0.05), glucose concentration (7.67 mmol / L versus 4.9 -5.1 mmol / L, p <0.05).Conclusions.Thus, it is advisable to involve survivors after COVID-19 in medical rehabilitation programs for faster and better recovery of the functions of various systems (primarily respiratory and cardiovascular), improving the quality of life and reducing the risk of disability.

Hali tarjima qilinmagan